

ASX ANNOUNCEMENT
1 April 2011

BNC105 Data Presented at AACR Conference

1 April 2011; Adelaide, Australia: Bionomics Limited (ASX:BNO; ADR:BMICY) today announced that its leading vascular disrupting agent (VDA), BNC105, would be the subject of two poster presentations at the prestigious annual American Association for Cancer Research (AACR) conference in Orlando, USA.

Data to be presented includes the VDA effects of BNC105 in two mouse models of renal cancer, including a model in which the cancer spreads to the lungs. BNC105 was shown to induce tumor blood vessel shutdown in both the primary tumor and the secondary lung cancer. BNC105 activity was shown to be comparable to that of the blockbuster drug Sutent which had worldwide sales of US\$1.066 billion in 2010. Sutent is used in first line therapy of renal cancer.

A second poster describes the efficacy of BNC105 in mouse models of mesothelioma and lung cancer. In the mesothelioma tumor model the survival benefit of BNC105 treatment surpassed that of Alimta which is used in the treatment of human mesothelioma. The worldwide sales of Alimta in 2010 were US\$2.208 billion.

BNC105 is currently in Phase II clinical trials in patients with renal cancer and in patients with mesothelioma. Bionomics anticipates reporting initial data from these trials in coming months. The preclinical data reported at AACR strongly supports these ongoing clinical trials.

Details of the scheduled poster presentations and their respective AACR abstracts are shown below.

Title:	Evaluation of the anti-cancer effects of the tumor selective vascular disruption agent BNC105 in preclinical renal cancer models.
Authors:	Tina C Lavranos (presenter), Annabell F Leske, Donna M Beaumont, Jelena Gasic and Gabriel Kremmidiotis
Session ID:	Experimental and Molecule Therapeutics 4
Session:	Sunday, April 3, 2011, 1:00 PM - 5:00 PM
Location:	Exhibit Hall A4-C, Poster Section 28
Abstract Number:	662

Title:	Anti-tumor activity of the vascular disruption agent BNC105 in models of mesothelioma and lung cancer.
Authors:	Annabell F Leske (presenter), Donna M Beaumont, Tina C Lavranos, Jelena Gasic and Gabriel Kremmidiotis
Session ID:	Experimental and Molecule Therapeutics 24
Session:	Tuesday, April 5, 2011, 8:00 AM - 12:00 PM
Location:	Exhibit Hall A4-C, Poster Section 27
Abstract Number:	3543

The posters can be found on the Bionomics website www.bionomics.com.au

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited

Dr Deborah Rathjen
CEO & Managing Director
+618 8354 6101 / 0418 160 425
drathjen@bionomics.com.au

Monsoon Communications

Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

The Trout Group

Lauren Glaser
+1 646 378 2972
lglaser@troutgroup.com

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNC105, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders and depression based on BNC210 which has recently completed Phase Ib clinical trials. Both compounds offer blockbuster potential if successfully developed.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system. These platforms underpin Bionomics' established business strategy and Bionomics is committed to securing partners for its key compounds.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of either BNC105 or BNC210, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.